Keyphrases
Receptor Agonist
100%
Glucagon-like
100%
Metabolic Syndrome
100%
Early Use
100%
Comorbid
100%
Obstructive Sleep Apnea
100%
A1 Receptor
100%
Diabetes Syndrome
100%
Diabetes
57%
Obesity
28%
Quality of Life
28%
Polypharmacy
28%
Atherosclerotic Cardiovascular Disease (ASCVD)
28%
Hypertension
14%
Type 2 Diabetes Mellitus (T2DM)
14%
Comorbidity
14%
Living with
14%
Health Care Costs
14%
Congestive Heart Failure
14%
Obesity-related Hypertension
14%
Pharmacologic Interventions
14%
Extant Literature
14%
Cardiometabolic Disease
14%
Multiple Effects
14%
Co-occurring Conditions
14%
Exenatide
14%
Adverse Drug Events
14%
Liraglutide
14%
Multiple Medications
14%
One-stop-shop
14%
Glucagon-like peptide-1 Receptor (GLP-1R)
14%
Semaglutide
14%
Albiglutide
14%
Lixisenatide
14%
Dulaglutide
14%
Medicine and Dentistry
Diabetes
100%
Metabolic Syndrome
100%
Obstructive Sleep Apnea
100%
Glucagon-Like Peptide-1 Agonist
100%
Health Care Cost
28%
Quality of Life
28%
Polypharmacy
28%
Apoplexy
14%
Drug Therapy
14%
Maturity Onset Diabetes of the Young
14%
Adverse Drug Reaction
14%
Congestive Heart Failure
14%
Liraglutide
14%
Exenatide
14%
Semaglutide
14%
Lixisenatide
14%
Albiglutide
14%
Dulaglutide
14%
Comorbidity
14%
Pharmacology, Toxicology and Pharmaceutical Science
Metabolic Syndrome X
100%
Sleep Disordered Breathing
100%
Glucagon Like Peptide 1 Receptor Agonist
100%
Coronary Artery Atherosclerosis
28%
Polypharmacy
28%
Congestive Heart Failure
14%
Adverse Drug Reaction
14%
Exendin 4
14%
Cerebrovascular Accident
14%
Liraglutide
14%
Semaglutide
14%
Albiglutide
14%
Lixisenatide
14%
Dulaglutide
14%
Comorbidity
14%
Non Insulin Dependent Diabetes Mellitus
14%